- Home
- IRMD vs PHAR Comparison
IRMD vs PHAR Comparison
Compare IRMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- PHAR
- Stock Information
- Founded
- IRMD 1992
- PHAR 1988
- Country
- IRMD United States
- PHAR Netherlands
- Employees
- IRMD N/A
- PHAR N/A
- Industry
- IRMD Medical/Dental Instruments
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- PHAR Health Care
- Exchange
- IRMD Nasdaq
- PHAR Nasdaq
- Market Cap
- IRMD 756.5M
- PHAR 731.1M
- IPO Year
- IRMD 2014
- PHAR N/A
- Fundamental
- Price
- IRMD $58.02
- PHAR $10.00
- Analyst Decision
- IRMD Strong Buy
- PHAR Strong Buy
- Analyst Count
- IRMD 1
- PHAR 3
- Target Price
- IRMD $72.00
- PHAR $30.00
- AVG Volume (30 Days)
- IRMD 67.2K
- PHAR 3.6K
- Earning Date
- IRMD 07-31-2025
- PHAR 07-31-2025
- Dividend Yield
- IRMD 1.14%
- PHAR N/A
- EPS Growth
- IRMD 10.72
- PHAR N/A
- EPS
- IRMD 1.55
- PHAR N/A
- Revenue
- IRMD $75,154,639.00
- PHAR $320,708,000.00
- Revenue This Year
- IRMD $10.62
- PHAR $13.31
- Revenue Next Year
- IRMD $9.69
- PHAR $7.68
- P/E Ratio
- IRMD $38.37
- PHAR N/A
- Revenue Growth
- IRMD 11.04
- PHAR 24.13
- 52 Week Low
- IRMD $42.34
- PHAR $6.65
- 52 Week High
- IRMD $63.29
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- IRMD 46.18
- PHAR 43.61
- Support Level
- IRMD $58.44
- PHAR $9.99
- Resistance Level
- IRMD $60.85
- PHAR $10.59
- Average True Range (ATR)
- IRMD 1.62
- PHAR 0.35
- MACD
- IRMD -0.40
- PHAR -0.14
- Stochastic Oscillator
- IRMD 8.87
- PHAR 7.45
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.